PHARMACIST SUBSTITUTION AUTHORITY FOR BIOSIMILARS: LEGAL FRAMEWORK AND JUDICIAL INTERPRETATION

1. INTRODUCTION

Pharmacist substitution authority for biosimilars refers to the legal power of a pharmacist to dispense an approved biosimilar medicine instead of the biological medicine prescribed by a healthcare professional. Biosimilars are biological products demonstrated to be highly similar to an already authorised reference biological medicine, with no clinically meaningful differences in safety, purity and potency.

Unlike ordinary generic medicines, biosimilars are produced through complex biological processes. Consequently, automatic substitution raises questions concerning patient safety, prescribing authority, informed consent, pharmacovigilance and professional accountability. The law must balance affordable access to medicines with appropriate clinical supervision.

2. LEGAL AND REGULATORY FRAMEWORK IN INDIA

India regulates biological medicines primarily through the Drugs and Cosmetics Act, 1940, the Drugs Rules, 1945, and the New Drugs and Clinical Trials Rules, 2019.

The Indian regulatory framework also includes the Central Drugs Standard Control Organisation (CDSCO) and the Department of Biotechnology's Guidelines on Similar Biologics, 2016.

The principal legal considerations include:

Regulatory approval of the biosimilar before marketing.

Demonstration of similarity with the reference biological product.

Compliance with manufacturing quality and safety standards.

Appropriate prescription and dispensing by authorised professionals.

Monitoring and reporting of adverse drug reactions.

Protection of patient interests through proper counselling and medical supervision.

Importantly, Indian law does not establish a universal automatic pharmacist-substitution entitlement for every approved biosimilar. Approval as a similar biologic should not automatically be interpreted as permission for unrestricted pharmacy-level interchangeability.

3. PHARMACIST'S SUBSTITUTION AUTHORITY

A pharmacist's authority depends on applicable legislation, prescription conditions, professional regulations and the particular medicine involved.

The following safeguards are important:

Prescriber authority: Substitution must respect the prescribing professional's directions and applicable legal restrictions.

Product identification: The pharmacist should verify the biosimilar's regulatory approval and manufacturer.

Patient safety: Switching should consider treatment history, dosage, administration and relevant clinical circumstances.

Documentation: The dispensed product, manufacturer and batch number should be recorded.

Pharmacovigilance: Suspected adverse reactions should be reported through appropriate regulatory channels.

Patient information: Patients should receive appropriate information about the medicine supplied.

4. INTERNATIONAL REGULATORY APPROACH

A. UNITED STATES

The Biologics Price Competition and Innovation Act, 2009, establishes the framework for biosimilar approval. Under Section 351(k) of the Public Health Service Act, FDA approval of interchangeability requires additional statutory criteria.

A pharmacist may substitute an FDA-designated interchangeable biosimilar, subject to state pharmacy laws. State legislation may require patient notification, prescriber notification, recordkeeping and compliance with a prescriber's prohibition against substitution. The FDA's Purple Book helps identify licensed biological products and their interchangeability status.

B. EUROPEAN UNION

The European Medicines Agency (EMA) and Heads of Medicines Agencies (HMA) issued a joint statement in 2022, supporting the scientific interchangeability of EU-approved biosimilars. However, individual Member States retain authority over pharmacy-level automatic substitution.

Thus, scientific interchangeability and legal substitution authority remain separate questions.

5. IMPORTANT JUDICIAL PRECEDENTS

There is no established body of reported Indian Supreme Court judgments directly determining pharmacists' automatic substitution authority for biosimilars. The following judgments provide analogous principles concerning professional responsibility, medical negligence, informed consent and pharmaceutical regulation.

1. Poonam Verma v. Ashwin Patel (1996) 4 SCC 332

Authority: Analogous. The Supreme Court distinguished authorised medical practice from treatment undertaken without appropriate professional qualifications. The decision supports the principle that healthcare professionals must operate within their legally recognised professional competence.

2. Dr. Laxman Balkrishna Joshi v. Dr. Trimbak Bapu Godbole, AIR 1969 SC 128

Authority: Analogous. The Supreme Court recognised the professional duty of care owed by medical practitioners. This principle is relevant when considering the responsibility of pharmacists to verify medicines and avoid negligent dispensing.

3. Indian Medical Association v. V.P. Shantha (1995) 6 SCC 651

Authority: Analogous. The judgment addressed the applicability of consumer protection law to medical services. It supports accountability for deficient healthcare services, including relevant professional dispensing activities.

4. Spring Meadows Hospital v. Harjol Ahluwalia (1998) 4 SCC 39

Authority: Analogous. The Supreme Court recognised liability arising from medical negligence and deficient healthcare services. It reinforces the importance of proper professional supervision and patient protection.

5. Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1

Authority: Analogous. The Supreme Court emphasised informed consent and the patient's right to understand medical interventions. Its reasoning supports transparent communication when a medicine is changed, particularly where clinical considerations are involved.

6. Kusum Sharma v. Batra Hospital (2010) 3 SCC 480

Authority: Analogous. The Supreme Court discussed the standards applicable to medical negligence and professional judgment. It provides guidance for evaluating whether healthcare professionals exercised reasonable care in their decisions.

7. Sandoz Inc. v. Amgen Inc., 582 U.S. 1 (2017)

Authority: Direct to biosimilar regulatory interpretation; not direct to pharmacist substitution. The US Supreme Court interpreted important provisions of the Biologics Price Competition and Innovation Act, including biosimilar approval and patent-dispute procedures. It clarifies the statutory distinction between biosimilar development and regulatory authorisation, although it does not decide pharmacists' substitution powers.

6. LEGAL LIABILITY AND COMPLIANCE REQUIREMENTS

Pharmacists may face professional, civil or regulatory consequences where substitution violates applicable law or causes harm through negligent dispensing.

Important compliance requirements include:

Confirming the regulatory status of the biological product.

Checking whether substitution is legally permitted.

Respecting any prescriber prohibition.

Maintaining accurate dispensing and batch records.

Informing patients whenever legally required.

Reporting suspected adverse reactions.

Maintaining appropriate cold-chain and storage conditions.

Referring clinically significant switching decisions to the prescriber.

Manufacturers and distributors also have responsibilities concerning product quality, traceability, labelling and pharmacovigilance.

7. CONCLUSION

Pharmacist substitution authority for biosimilars is an important intersection of pharmaceutical regulation, professional licensing, patient rights and public health. Regulatory approval as a biosimilar does not automatically create unrestricted substitution authority.

In India, pharmacists must comply with applicable drug-control and pharmacy legislation, professional standards and prescription requirements. The US model provides a more explicit statutory framework for interchangeable biosimilar substitution, while the EU separates scientific interchangeability from national pharmacy-level substitution decisions.

Ultimately, a legally sound substitution system must ensure patient safety, professional accountability, accurate documentation and effective pharmacovigilance while improving access to affordable biological medicines.